Aprea Therapeutics, Inc. ( (APRE) ) has released its Q4 earnings. Here is a breakdown of the information Aprea Therapeutics, Inc. presented to its investors.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells. The company operates primarily in the oncology sector, with a unique approach to cancer therapy that aims to reduce the toxicity associated with traditional treatments.
In its latest earnings report, Aprea Therapeutics highlighted significant progress in its clinical trials and financial performance for the fourth quarter and full year of 2024. The company is advancing its pipeline with promising developments in its lead programs, APR-1051 and ATRN-119, aimed at treating difficult-to-treat cancers.
Key financial metrics from the report include a net loss of $2.9 million for the fourth quarter, an improvement from the previous year’s loss of $3.4 million. Research and development expenses increased to $2.4 million, reflecting the company’s investment in its clinical trials. Aprea ended the year with $22.8 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2026.
Strategically, Aprea is making strides with its ACESOT-1051 and ABOYA-119 trials. The ACESOT-1051 trial is exploring the WEE1 kinase inhibitor APR-1051, with patient enrollment ongoing and preliminary efficacy data anticipated in the second half of 2025. Meanwhile, the ABOYA-119 trial is evaluating the ATR inhibitor ATRN-119, with the potential to optimize dosing for better clinical outcomes.
Looking ahead, Aprea Therapeutics remains focused on advancing its clinical programs and transforming cancer treatment paradigms. The company’s management is optimistic about the potential of its DDR-based therapies to address high unmet medical needs in oncology.